Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Common Equity (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Common Equity data on record, last reported at $103.1 million in Q4 2025.

  • For Q4 2025, Common Equity fell 33.73% year-over-year to $103.1 million; the TTM value through Dec 2025 reached $103.1 million, down 33.73%, while the annual FY2025 figure was $103.1 million, 33.73% down from the prior year.
  • Common Equity reached $103.1 million in Q4 2025 per ACRS's latest filing, down from $120.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $235.8 million in Q2 2022 and bottomed at $103.1 million in Q4 2025.
  • Average Common Equity over 5 years is $166.2 million, with a median of $156.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 431.4% in 2021, then tumbled 33.73% in 2025.
  • A 5-year view of Common Equity shows it stood at $197.3 million in 2021, then increased by 0.14% to $197.6 million in 2022, then dropped by 20.46% to $157.2 million in 2023, then dropped by 1.03% to $155.6 million in 2024, then tumbled by 33.73% to $103.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $103.1 million in Q4 2025, $120.1 million in Q3 2025, and $131.7 million in Q2 2025.